Candel Therapeutics, Inc. (CADL)
Automate Your Wheel Strategy on CADL
With Tiblio's Option Bot, you can configure your own wheel strategy including CADL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CADL
- Rev/Share 0.0
- Book/Share 1.4792
- PB 3.9548
- Debt/Equity 0.134
- CurrentRatio 4.6414
- ROIC -0.3926
- MktCap 293100795.0
- FreeCF/Share -0.5391
- PFCF -10.7706
- PE -7.4619
- Debt/Assets 0.1044
- DivYield 0
- ROE -1.3674
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CADL | Citigroup | -- | Buy | -- | $25 | Feb. 20, 2025 |
| Initiation | CADL | Canaccord Genuity | -- | Buy | -- | $20 | Feb. 19, 2025 |
| Initiation | CADL | BofA Securities | -- | Buy | -- | $15 | Feb. 7, 2025 |
News
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Candel stock rises as FDA grants RMAT tag to CAN-2409 after phase III success in prostate cancer. BLA submission is planned at the end of 2026.
Read More
Candel Therapeutics get FDA's RMAT designation for prostate cancer therapy
Published: May 28, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) said on Wednesday the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate, CAN-2409, for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease. The RMAT designation is intended to expedite the development and review of regenerative therapies for serious conditions where preliminary evidence suggests the drug may address unmet medical needs.
Read More
Candel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025
Published: May 23, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) announced that it will present results from its positive Phase 3 trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3 in Chicago. “We are honored that our pivotal phase 3 CAN-2409 data will be presented at the ASCO Annual Meeting, reinforcing the strength of our previously announced results,” Candel CEO Dr Paul Peter Tak said in a statement.
Read More
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that results from the Company's positive phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) in patients with intermediate-to-high-risk localized prostate cancer will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 30 to June 3, 2025.
Read More
Best Momentum Stocks to Buy for May 19th
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
CADL, HMN and MAG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 19, 2025.
Read More
New Strong Buy Stocks for May 19th
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
SUBCY, MAG, KARO, CADL and BPOP have been added to the Zacks Rank #1 (Strong Buy) List on May 19, 2025.
Read More
Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 311% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Candel Therapeutics to Present at Upcoming Investor Conferences
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that management will present and participate in one-on-one meetings with investors at upcoming investor conferences.
Read More
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409
Published: April 01, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) shared promising results from a Phase 1b clinical trial testing its experimental cancer therapy, CAN-2409, in patients with newly diagnosed high-grade glioma—a particularly aggressive form of brain cancer. The study, published in Neuro-Oncology, found that CAN-2409, when combined with the immunotherapy drug nivolumab and standard treatments like surgery, radiation, and chemotherapy, was well tolerated and showed signs of boosting the immune system's response to tumors.
Read More
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Candel Therapeutics (CADL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Candel Therapeutics partners with IDEA Pharma on commercialization of lead asset CAN-2409
Published: March 20, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) announced that it has partnered with IDEA Pharma to advance the commercialization of its lead immunotherapy candidate CAN-2409. The collaboration follows positive Phase 3 data showing CAN-2409 significantly improved disease-free survival in patients with intermediate-to-high-risk localized prostate cancer.
Read More
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, together with IDEA Pharma, a Division of SAI MedPartners (IDEA), a pioneering biopharmaceutical strategy consultancy, today announced a strategic commercial partnership.
Read More
Candel Therapeutics appoints cancer immunology expert to research advisory board
Published: March 18, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) said on Tuesday it has appointed Dr Elizabeth Jaffee to its research advisory board. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology and Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Read More
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial results - ICYMI
Published: February 28, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) CEO Dr Paul Peter Tak talked with Proactive about the encouraging results from the phase 2 trial of its investigational medicine CAN-2409 for borderline resectable pancreatic cancer. Dr Tak shared that the median overall survival in the active treatment group reached 31.4 months, compared to just 12.5 months in the control group, showing a clear separation of survival curves.
Read More
Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Positive
Candel Therapeutics' recent phase 2 results in pancreatic cancer showed promising median survival but led to a 20% stock drop due to market skepticism. Despite the drop, I maintain a "Buy" sentiment, emphasizing the significant potential in prostate cancer and the unjustified negative reaction to positive news. CADL's financial health improved with a $92 million share offering, extending their runway to over three years, supporting their ongoing projects.
Read More
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEEDHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced final overall survival data from the completed randomized controlled phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection, in patients with borderline resectable PDAC.
Read More
About Candel Therapeutics, Inc. (CADL)
- IPO Date 2021-07-27
- Website https://www.candeltx.com
- Industry Biotechnology
- CEO Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
- Employees 38